NCT06553781View on ClinicalTrials.gov

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma

NANot yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2027

Conditions
Malignant Melanoma
Interventions
DRUG

Temozolomide、Fruquintinib、Cadonilimab

"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."

All Listed Sponsors
lead

Fudan University

OTHER

NCT06553781 - A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | Biotech Hunter | Biotech Hunter